1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, August 2018 (p3)

Cancer Analysis & Statistics in European Union, August 2018 (p3)

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

61-90 of about 100 reports

Iressa

  • $ 10000
  • August 2018
  • 21 pages

Drug Overview Iressa (gefitinib; AstraZeneca) is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. The receptor is expressed on the cell surface of both normal ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Gilotrif

  • $ 10000
  • August 2018
  • 37 pages

Drug Overview Gilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Dacomitinib

  • $ 10000
  • August 2018
  • 18 pages

Drug Overview Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Renal Cell Cancer Pricing, Reimbursement, and Access

  • $ 2995
  • August 2018
  • 91 pages

Overview There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild. Spend in RCC is among the top five oncology indications. Although ...

  • Cancer
  • Renal Cancer
  • European Union
  • Japan
  • United States

Velcade

  • $ 10000
  • August 2018
  • 31 pages

Drug Overview Velcade (bortezomib; Takeda/Johnson and Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death. ...

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • European Union

Kyprolis

  • $ 10000
  • August 2018
  • 36 pages

Drug Overview Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Darzalex

  • $ 10000
  • August 2018
  • 37 pages

Drug Overview Darzalex (daratumumab; Johnson and Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in othe ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • Product Initiative

Bladder Cancer Market and Forecast Analysis

  • $ 22000
  • July 2018
  • 199 pages

Disease Overview Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary ...

  • Bladder Cancer
  • Cancer
  • European Union
  • United States
  • Market Size

Acute Lymphobastic Leukemia Forecast and Market Analysis to 2024

  • $ 22000
  • July 2018
  • 175 pages

Disease Overview Acute lymphoblastic leukemia (ALL) is a hematological disease that is characterized by the proliferation of immature lymphoid cells in the bone marrow and peripheral blood. ALL is typically ...

  • Cancer
  • Leukemia
  • European Union
  • Japan
  • Demand

Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

  • $ 22000
  • June 2018
  • 225 pages

DISEASE OVERVIEW Glioblastoma (GBM) is the most common and most aggressive type of malignant primary brain tumor. It is a malignant glioma that develops from astrocytes, which are star-shaped glial cells ...

  • Brain Cancer
  • Cancer
  • European Union
  • United States
  • Demand

Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • May 2018
  • 505 pages

DISEASE OVERVIEW Ovarian cancer is defined as a group of tumors that originate in the ovaries. Epithelial ovarian cancer is the prevailing cause of death from gynecological malignancies in the Western ...

  • Cancer
  • Ovarian Cancer
  • European Union
  • United States
  • Demand

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • $ 22000
  • April 2018
  • 196 pages

Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3–6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • $ 22000
  • April 2018
  • 229 pages

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of ...

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • $ 22000
  • April 2018
  • 162 pages

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

Ovarian Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • March 2018
  • 159 pages

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascula ...

  • Cancer
  • Ovarian Cancer
  • Therapy
  • European Union
  • United States

Drug Overview: Rubraca

  • $ 10000
  • January 2018
  • 29 pages

Drug Overview Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • Market Description

Drug Overview: ipatasertib

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview  Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • Japan

Drug Overview: apalutamide

  • $ 10000
  • January 2018
  • 18 pages

Drug Overview  Apalutamide (Johnson&Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • United States

Drug Overview: darolutamide

  • $ 10000
  • January 2018
  • 17 pages

Drug Overview  Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Cancer
  • Hormone
  • Prostate Cancer
  • Therapy
  • European Union

Drug Overview: DCVAC/PCa

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Cancer
  • Cell Therapy
  • Medical Biotechnology
  • Prostate Cancer
  • European Union

Drug Overview: Zytiga

  • $ 10000
  • January 2018
  • 21 pages

Drug Overview Zytiga (abiraterone acetate; Johnson&Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Cancer
  • Hormone
  • Therapy
  • European Union
  • Supply

Drug Overview: Xtandi

  • $ 10000
  • January 2018
  • 19 pages

Drug Overview Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Overview: Xofigo

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Overview: Tecentriq

  • $ 10000
  • January 2018
  • 82 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug Overview: Masitinib

  • $ 10000
  • January 2018
  • 45 pages

Drug Overview Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • Prostate Cancer
  • European Union

Drug Overview: Jevtana

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Cancer
  • Prostate Cancer
  • Therapy
  • European Union
  • Japan

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

  • $ 22000
  • January 2018
  • 699 pages

DISEASE OVERVIEW Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to ...

  • Cancer
  • Prostate Cancer
  • European Union
  • United States
  • Demand

Drug Analysis: Rubraca

  • $ 10000
  • January 2018
  • 29 pages

Drug Overview Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • United States

Drug Analysis: ipatasertib

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • Japan

Drug Analysis: apalutamide

  • $ 10000
  • January 2018
  • 18 pages

Drug Overview Apalutamide (Johnson and Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • United States

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on